Background Previous studies have shown that the incidence of idiopathic pulmonary fibrosis (IPF) is rising in the UK and USA. Death registrations and primary care data were used to determine the ...

In our trial, we investigated the efficacy and safety of pirfenidone versus placebo in addition to standard of care in patients with progressive fibrotic ILD due to idiopathic non-specific ...

Only 2 disease-modifying idiopathic pulmonary fibrosis (IPF) therapies have been approved by the US Food and Drug Administration (FDA) as of June 2025. They do not stop or cure the disease, so the use ...

Introduction Idiopathic pulmonary fibrosis (IPF) is a lung disease of unknown cause characterised by progressive scarring, with limited effective treatment and a median survival of only 2–3 years. Our ...

CAMBRIDGE, Mass., June 3, 2025 /PRNewswire/ -- Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, reshaping the landscape from target identification to personalized ...

On June 3, 2025, the industry's first proof-of-concept clinical validation of AI-driven drug discovery was published in Nature Medicine.Insilico Medicine and collaborators reported promising safety ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in ...

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in ...